JP2010536752A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536752A5
JP2010536752A5 JP2010521009A JP2010521009A JP2010536752A5 JP 2010536752 A5 JP2010536752 A5 JP 2010536752A5 JP 2010521009 A JP2010521009 A JP 2010521009A JP 2010521009 A JP2010521009 A JP 2010521009A JP 2010536752 A5 JP2010536752 A5 JP 2010536752A5
Authority
JP
Japan
Prior art keywords
methyl
amino
carbamoyloxy
fluorophenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521009A
Other languages
English (en)
Japanese (ja)
Other versions
JP5670731B2 (ja
JP2010536752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009636 external-priority patent/WO2009023193A1/en
Publication of JP2010536752A publication Critical patent/JP2010536752A/ja
Publication of JP2010536752A5 publication Critical patent/JP2010536752A5/ja
Application granted granted Critical
Publication of JP5670731B2 publication Critical patent/JP5670731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521009A 2007-08-15 2008-08-11 ある種の化学物質、組成物、および方法 Expired - Fee Related JP5670731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96502007P 2007-08-15 2007-08-15
US60/965,020 2007-08-15
PCT/US2008/009636 WO2009023193A1 (en) 2007-08-15 2008-08-11 Certain chemical entities, compositions, and methods

Publications (3)

Publication Number Publication Date
JP2010536752A JP2010536752A (ja) 2010-12-02
JP2010536752A5 true JP2010536752A5 (enExample) 2014-01-09
JP5670731B2 JP5670731B2 (ja) 2015-02-18

Family

ID=40350992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521009A Expired - Fee Related JP5670731B2 (ja) 2007-08-15 2008-08-11 ある種の化学物質、組成物、および方法

Country Status (14)

Country Link
US (3) US8088793B2 (enExample)
EP (1) EP2195328A4 (enExample)
JP (1) JP5670731B2 (enExample)
KR (1) KR20100044251A (enExample)
CN (1) CN101821279A (enExample)
AR (1) AR069364A1 (enExample)
AU (1) AU2008287435B2 (enExample)
CA (1) CA2696321A1 (enExample)
CL (1) CL2008002411A1 (enExample)
MX (1) MX2010001692A (enExample)
NZ (1) NZ583351A (enExample)
PE (1) PE20090958A1 (enExample)
TW (1) TWI426908B (enExample)
WO (1) WO2009023193A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
MX2013006101A (es) 2010-12-17 2013-07-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
EP2834269A4 (en) * 2012-04-02 2015-12-30 Cytokinetics Inc METHODS FOR IMPROVING DIAPHRAGM FUNCTION
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2018243770A1 (en) 2017-03-30 2019-09-19 F. Hoffmann-La Roche Ag Isoquinolines as inhibitors of HPK1
JP7154221B2 (ja) 2017-03-30 2022-10-17 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Hpk1の阻害剤としてのナフチリジン
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
JP7386842B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227709A (en) 1961-11-28 1966-01-04 Merck & Co Inc Derivatives of cephalosporin c and process
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2851953A1 (de) * 1978-12-01 1980-06-19 Thomae Gmbh Dr K Neue spectinomycylamine, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel
JP2838148B2 (ja) 1991-08-15 1998-12-16 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
JPH07247274A (ja) 1994-03-10 1995-09-26 Wakamoto Pharmaceut Co Ltd ピバル酸 テトラゾリルフェニルエステル誘導体、それらを有効成分として含有するエラスターゼ阻害剤及び肺障害治療剤
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
WO1998041510A1 (en) * 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Novel benzolactam derivatives and medicinal compositions comprising the same
NZ503782A (en) 1997-11-18 2002-03-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and chemokine receptor antagonists that are effective in treating disease caused by infiltration of the tissue by blood leukocytes
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
GB9807833D0 (en) * 1998-04-09 1998-06-10 Boc Group Plc Separation of air
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6362177B1 (en) * 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
AR038368A1 (es) 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
EP1534693A2 (en) 2002-09-06 2005-06-01 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
NZ540878A (en) * 2003-01-14 2008-06-30 Cytokinetics Inc Compounds, compositions and methods
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
WO2005016883A2 (en) * 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
JP4380508B2 (ja) * 2003-11-28 2009-12-09 田辺三菱製薬株式会社 医薬組成物
EP1711175A1 (en) * 2004-02-04 2006-10-18 Active Biotech AB Diurea derivatives
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
JPWO2006137350A1 (ja) * 2005-06-22 2009-01-15 キッセイ薬品工業株式会社 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2007056078A2 (en) 2005-11-02 2007-05-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2007143822A1 (en) 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
US8071625B2 (en) 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2008016676A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US8063082B2 (en) 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods

Similar Documents

Publication Publication Date Title
JP2010536752A5 (enExample)
US12157733B2 (en) Aminotriazolopyridines as kinase inhibitors
US11053234B2 (en) 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
US11618753B2 (en) Aminopyrrolotriazines as kinase inhibitors
JP6056872B2 (ja) イミダゾピリジン化合物
US11440913B2 (en) Aminoimidazopyridazines as kinase inhibitors
JP5552539B2 (ja) Cns障害の処置のためのオキサゾリン誘導体
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
KR20140042848A (ko) Cb2 작용제로서 유용한 피리딘-2-아미드
KR20180110132A (ko) 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
US20160016907A1 (en) Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016153023A1 (ja) 新規オキサジアゾール誘導体及びこれを含有する医薬
RU2605600C2 (ru) Амино-замещенные производные 3-гетероароиламинопропионовой кислоты и их применение в качестве фармацевтических средств
JP2012502035A (ja) ロイコトリエン産生のインドリジン阻害剤
US8394837B2 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CA3153083A1 (en) Indazole carboxamides as kinase inhibitors
JP2020510007A (ja) オピオイド受容体調節因子としての多環式アミン
US20220009918A1 (en) Chemical Compounds
JP2023520005A (ja) Sstr4アゴニストとしてのn-ヘテロアリールアルキル-2-(ヘテロシクリル及びヘテロシクリルメチル)アセトアミド誘導体
JP2017521453A (ja) ピリジル−トリアザビシクル
JP2025500907A (ja) PLpro阻害剤
CN113015736B (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
WO2023279986A1 (zh) 六元芳基或杂芳基酰胺类化合物及其组合物和用途
WO2018079628A1 (ja) 縮環ピロール誘導体およびその医薬用途
AU2023318665A1 (en) Novel compound as hypoxia-inducible factor 1(hif-1) inhibitor or vascular endothelial growth factor (vegf) inhibitor, and pharmaceutical composition comprising same